Rapid communication · 29 May 2025
Conference abstractPublished 2018
Clinical and pharmacological basis for the use of Aliskiren in diabetes mellitus patients with peripheral neuropathy
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Statement of the Problem: Diabetes mellitus is a challenging problem in modern medicine. Over 347 million people worldwide suffer from diabetes. Polyneuropathy is the most common complication of diabetes mellitus (60-70% of patients). Its treatment still remains unresolved. The optimal therapy involves: Blood glucose level control, anticonvulsants, antidepressants and opioid administration, though it does not change pathogenic pattern. It has been identified that Tumor Necrosis Factor alpha (TNFα) and Renin-Angiotensin Aldosteron System (RAAS) play a significant role in type-1 and type-2 diabetes development. The data collected in the present-day scientific literature indicate the essential pathogenic role of TNFα in the development of diabetic neuropathy (DNP). In our study we use Aliskiren (renin inhibitor) to study modulatory impact on TNFα. Methodology & Theoretical Orientation: The study population consists of 60 individuals diagnosed with diabetes mellitus (DM) with DNP. The enrolled subjects are divided into two main groups: Group-1 with type-1 and type-2 diabetes mellitus, complicated by DNP to take Aliskiren and group-2 with the same pathology, proceeding with the treatment without Aliskiren but given Telmisartan (ARB), for certainty of Aliskiren efficacy. At the start of the trial and on completion of the six weeks period TNFa level and C-peptide (for T2DM) will be determined. Findings: Aliskiren improves conditions of T2DM patients with DNP. Namely, the symptoms of neuropathy are reduced, the blood TNFa level is reduced and C-peptide level is increased. Conclusion & Significance: Our results confirm hypothesis that TNFα may play a substantial role in the development and progression of type-2 diabetes mellitus as well as in pathogenesis of diabetic neuropathy. Aliskiren has modulatory impact on TNFα, so we will have results for clinical and pharmacological analysis of Aliskiren application in diabetic neuropathy.
Subjects
Diabetes & EndocrinologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Diabetes & Metabolism.
Rapid communication · 29 May 2025
Genetic and epigenetic markers for gdm risk
Short communication · 29 May 2025
Metabolic syndrome: Diet, timed eating, supplements
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Diabetes & Metabolism
- SubjectDiabetes & Endocrinology
- BylineArticles whose byline prints “Anna Archvadze”